Archives of Orthopaedic and Trauma Surgery

, Volume 134, Issue 5, pp 679–683 | Cite as

Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention

  • Fucun Liu
  • Xiaobing Chu
  • Jiefeng Huang
  • Kun Tian
  • Jiang Hua
  • Peijian Tong
Knee Arthroplasty

Abstract

Background

The purpose of this study was to determine the safety and effectiveness, as assessed by risk of bleeding and incidence of deep venous thrombosis (DVT), of administering delayed low-molecular-weight heparin (LMWH) after total knee arthroplasty.

Methods

A prospective study of 210 consecutive patients undergoing primary unilateral total knee arthroplasty was undertaken. The patients were randomized into two groups: one of which was managed according to a standard LMWH program (LMWH-s group) and the other with delayed LMWH (LMWH-p). LMWH was initiated 12 h after wound closure in the LMWH-s group, and 24 h after wound closure in the LMWH-p group.

Results

The total blood loss in the first three postoperative days was calculated and all complications were recorded. The mean total blood loss was 435 and 387 mL in the LMWH-s group and LMWH-p group, respectively (p < 0.01). No significant difference in the incidence of symptomatic DVT was observed. The mean length of hospital stay was 7.29 days in the LMWH-s group and 6.56 days in the LMWH-p group (p < 0.05).

Conclusions

After total knee arthroplasty, LMWH-p is safer for bleeding than LMWH-s and equally effective concerning prevention of DVT.

Keywords

Deep venous thrombosis Low-molecular-weight heparin Medication Anticoagulation Total blood loss 

References

  1. 1.
    Hirsh J, Guyatt G, Lewis SZ (2008) Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines. Chest 133(6):1293–1295. doi:10.1378/chest.08-0782 PubMedCrossRefGoogle Scholar
  2. 2.
    Dorr LD, Gendelman V, Maheshwari AV, Boutary M, Wan Z, Long WT (2007) Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am 89(12):2648–2657. doi:10.2106/JBJS.F.00235 PubMedCrossRefGoogle Scholar
  3. 3.
    Lie SA, Engesaeter LB, Havelin LI, Furnes O, Vollset SE (2002) Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand 73(4):392–399. doi:10.1080/00016470216312 PubMedCrossRefGoogle Scholar
  4. 4.
    Howie C, Hughes H, Watts AC (2005) Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 87(12):1675–1680. doi:10.1302/0301-620X.87B12.16298 PubMedCrossRefGoogle Scholar
  5. 5.
    Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487–2498. doi:10.1056/NEJMoa1006885 PubMedCrossRefGoogle Scholar
  6. 6.
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39. doi:10.1016/S0140-6736(08)60880-6 PubMedCrossRefGoogle Scholar
  7. 7.
    Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105(3):444–453. doi:10.1160/TH10-09-0601 PubMedGoogle Scholar
  8. 8.
    Jensen CD, Steval A, Partington PF, Reed MR, Muller SD (2011) Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br 93(1):91–95. doi:10.1302/0301-620X.93B1.24987 PubMedCrossRefGoogle Scholar
  9. 9.
    Kulshrestha V, Kumar S (2013) DVT prophylaxis after TKA: routine anticoagulation vs risk screening approach—a randomized study. J Arthroplasty. doi:10.1016/j.arth.2013.05.025 PubMedGoogle Scholar
  10. 10.
    Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R (2013) Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. Eur J Orthop Surg Traumatol 23(4):481–486. doi:10.1007/s00590-012-0987-y PubMedCrossRefGoogle Scholar
  11. 11.
    Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D et al (1993) A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329(19):1370–1376. doi:10.1056/NEJM199311043291902 PubMedCrossRefGoogle Scholar
  12. 12.
    RD Heparin Arthroplasty Group (1994) RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 76(8):1174–1185Google Scholar
  13. 13.
    Cho KY, Kim KI, Khurana S, Bae DK, Jin W (2013) Is routine chemoprophylaxis necessary for prevention of venous thromboembolism following knee arthroplasty in a low incidence population? Arch Orthop Trauma Surg 133(4):551–559. doi:10.1007/s00402-013-1691-z PubMedCrossRefGoogle Scholar
  14. 14.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949–956. doi:10.1016/S0140-6736(07)61445-7 PubMedCrossRefGoogle Scholar
  15. 15.
    Gross JB (1983) Estimating allowable blood loss: corrected for dilution. Anesthesiology 58(3):277–280PubMedCrossRefGoogle Scholar
  16. 16.
    Committee for Proprietary Medicinal Products (CPMP) (2004) Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates. Stat Med 23((5):701–709. doi:10.1002/sim.1647 Google Scholar
  17. 17.
    Thirugnanam S, Pinto R, Cook DJ, Geerts WH, Fowler RA (2012) Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. Crit Care 16(2):R43. doi:10.1186/cc11241 PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Lieberman JR, Barnes CL, Lachiewicz PF, Hanssen AD, Clarke HD, Pellegrini VD Jr (2009) Venous thromboembolism debate in joint arthroplasty. J Bone Joint Surg Am 91 Suppl 5:29–32. doi:10.2106/JBJS.I.00364 PubMedCrossRefGoogle Scholar
  19. 19.
    Enyart JJ, Jones RJ (2005) Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann Pharmacother 39(6):1002–1007. doi:10.1345/aph.1E536 PubMedCrossRefGoogle Scholar
  20. 20.
    Coventry MB, Nolan DR, Beckenbaugh RD (1973) “Delayed” prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties. J Bone Joint Surg Am 55(7):1487–1492PubMedGoogle Scholar
  21. 21.
    Fitzgerald RH, Spiro TE, Trowbridge AA, Gardiner GA, Whitsett TL, O’Connell MB, Ohar JA, Young TR (2001) Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 83-A(6):900–906PubMedGoogle Scholar
  22. 22.
    Lotke PA, Lonner JH (2005) Deep venous thrombosis prophylaxis: better living through chemistry—in opposition. J Arthroplasty 20(4 Suppl 2):15–17. doi:10.1016/j.arth.2005.03.002 PubMedCrossRefGoogle Scholar
  23. 23.
    Parvizi J, Azzam K, Rothman RH (2008) Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Arthroplasty 23(7 Suppl):2–5. doi:10.1016/j.arth.2008.06.028 PubMedCrossRefGoogle Scholar
  24. 24.
    Confalonieri N, Manzotti A, Pullen C (2004) Is closed-suction drain necessary in unicompartmental knee replacement? a prospective randomised study. Knee 11(5):399–402. doi:10.1016/j.knee.2003.10.001 PubMedCrossRefGoogle Scholar
  25. 25.
    Montoya RC, Gajra A (2012) Current status of new anticoagulants in the management of venous thromboembolism. Adv Hematol 2012:856341. doi:10.1155/2012/856341 PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Ageno W, Spyropoulos AC, Turpie AG (2012) Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thromb Haemost 107(6):1027–1034. doi:10.1160/TH11-11-0787 PubMedCrossRefGoogle Scholar
  27. 27.
    Nieto JA, Espada NG, Merino RG, Gonzalez TC (2012) Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 130(2):183–191. doi:10.1016/j.thromres.2012.02.011 PubMedCrossRefGoogle Scholar
  28. 28.
    McCullagh L, Tilson L, Walsh C, Barry M (2009) A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics 27(10):829–846. doi:10.2165/11313800-000000000-00000 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Fucun Liu
    • 1
  • Xiaobing Chu
    • 1
  • Jiefeng Huang
    • 1
  • Kun Tian
    • 1
  • Jiang Hua
    • 1
  • Peijian Tong
    • 1
  1. 1.Department of OrthopedicsThe First Affiliated Hospital of Zhejiang University of Traditional Chinese MedicineHangzhouChina

Personalised recommendations